Thursday, October 2, 2014

Lilly (LLY) gives up on Lupus Drug providing less competition for Immunomedics (IMMU) and Anthera (ANTH)

Lilly (LLY) terminated the development of Tabalumab which was being studied for potential treatment of systemic lupus erythematosis (SLE) after the drug did not show efficiency in two phase 3 trials.

Immunomedics (IMMU) and Anthera (ANTH) have drugs in phase 3 trials focused on SLE so this is good news on one hand as it's less competition but bad news on the other as it highlights how difficult this disease is to treat and the prospects of successful trial results of their compounds.  Immunomedics is expected to report top-line results of its compound in Q1 2015.

I own shares of both companies as I'm willing to make the gamble as the upside is significant for both companies.

No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com